Implications of baseline glycemic control by plasma glycated hemoglobin A1c on adverse outcomes in patients with coronary heart disease and type 2 diabetes mellitus: Results from the PROMISE study.
Tang XF, Li QX, Han YL, Wang XZ, Song Y, Zhang Z, Xu JJ, Liu ZY, Chen Y, Zhang YZ, Zhu P, Guo XG, Jiang L, Wang ZF, Liu R, Wang QS, Yao Y, Feng YQ, Zhao XY, Yuan JQ.
Tang XF, et al. Among authors: feng yq.
Heliyon. 2024 Oct 23;10(22):e39748. doi: 10.1016/j.heliyon.2024.e39748. eCollection 2024 Nov 30.
Heliyon. 2024.
PMID: 39584103
Free PMC article.